ACTU (Actuate Therapeutics) Additional Paid-In Capital: $166.09 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ACTU Actuate Therapeutics Inc ACTU
14 GF Score
Price $1.00
View Full Analysis

What is Actuate Therapeutics Additional Paid-In Capital?

Actuate Therapeutics ACTU -0.26% 14 Additional Paid-In Capital is $166.09 Mil as of Jun. 2026. GuruFocus rates ACTU with a GF Score™ of 14/100.


Actuate Therapeutics's quarterly additional paid-in capital increased from Dec. 2025 ($162.53 Mil) to Mar. 2026 ($164.02 Mil) and increased from Mar. 2026 ($164.02 Mil) to Jun. 2026 ($166.09 Mil).

Actuate Therapeutics's annual additional paid-in capital increased from Dec. 2023 ($5.47 Mil) to Dec. 2024 ($132.48 Mil) and increased from Dec. 2024 ($132.48 Mil) to Dec. 2025 ($162.53 Mil).

Actuate Therapeutics Additional Paid-In Capital Related Terms

Actuate Therapeutics Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Actuate Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actuate Therapeutics Additional Paid-In Capital Chart

Actuate Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
5.04 5.47 132.48 162.53

Actuate Therapeutics Quarterly Data
Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 141.99 160.99 162.53 164.02 166.09
ACTU
14GF Score
Actuate Therapeutics Inc ACTU
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actuate Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $166.09 Mil mean?
Actuate Therapeutics (ACTU) has a Additional Paid-In Capital of $166.09 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Actuate Therapeutics and its competitors.
Is Actuate Therapeutics' Additional Paid-In Capital too high?
Actuate Therapeutics' current Additional Paid-In Capital is $166.09 Mil. Overall, Actuate Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Actuate Therapeutics' Additional Paid-In Capital compare to CRVO and KPTI?
Actuate Therapeutics' Additional Paid-In Capital of $166.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Actuate Therapeutics and its competitors. Actuate Therapeutics's current Additional Paid-In Capital is $166.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actuate Therapeutics stock overvalued right now?
Actuate Therapeutics (ACTU) has a current Additional Paid-In Capital of $166.09 Mil. The current Additional Paid-In Capital is $166.09 Mil. Actuate Therapeutics' overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Actuate Therapeutics (ACTU), the current Additional Paid-In Capital is $166.09 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actuate Therapeutics Business Description

Address 1751 River Run, Suite 400, Fort Worth, TX, USA, 76107
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
14GF Score

Get the complete analysis for ACTU

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.00
Price